Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06680232 · ClinicalTrials.gov registry record · Phase 1
Phase 1 Study to Evaluate Safety and Antiviral Activity of PBGENE-HBV in Adult Patients With Chronic Hepatitis B
A Phase 1 study of Hepatitis B， Chronic, sponsored by Precision BioSciences.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 45
- Enrollment target
- 4
- Study locations
NCT06680232: Recruiting Phase 1 study of Hepatitis B， Chronic, sponsored by Precision BioSciences.
NCT06680232 is a Phase 1 study of Hepatitis B， Chronic that is actively recruiting participants, run by Precision BioSciences. The registered enrollment target is 45 participants, below the 599-participant average among 6 other Hepatitis B， Chronic trials with a reported enrollment target (92% lower). The trial reports 4 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06680232, a Phase 1 study of Hepatitis B， Chronic, is actively recruiting participants, sponsored by Precision BioSciences.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 45 participants
- Enrollment target
- 4
- Study locations
Study Summary
This is a Phase 1, open-label, dose escalation and dose expansion study to evaluate the safety, tolerability, PK, and antiviral activity of PBGENE-HBV in adult participants with chronic hepatitis B.
Primary Outcome
Frequency of TEAEs
Conditions Studied
Interventions
- BIOLOGICAL PBGENE-HBV
Study Locations (4)
Other
- ICS ARENSIA Exploratory Medicine SRL - Chisinau
- New Zealand Clinical Research - Auckland
Massachusetts
- Massachusetts General Hospital/Harvard University - Boston
Hong Kong
- Queen Mary Hospital, The University of Hong Kong - Hong Kong
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2024-11-14 |
| Est. Completion | 2026-12 |
| Phase | Phase 1 |
What NCT06680232 shows while recruiting
NCT06680232 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 45 participants, a relatively small participant target, below the 599-participant average among 6 other Hepatitis B， Chronic trials with a reported enrollment target (92% lower).
The record links to 1 condition, with Hepatitis B， Chronic appearing as the primary indexed condition, and to 1 intervention - of which PBGENE-HBV is the first listed.
NCT06680232 reports a single indexed study location in Other, Massachusetts, Hong Kong.
Frequently Asked Questions
What is clinical trial NCT06680232 about?
NCT06680232 is a clinical study titled "Phase 1 Study to Evaluate Safety and Antiviral Activity of PBGENE-HBV in Adult Patients With Chronic Hepatitis B". This is a Phase 1, open-label, dose escalation and dose expansion study to evaluate the safety, tolerability, PK, and antiviral activity of PBGENE-HBV in adult participants with chronic hepatitis B.
What is the current status of trial NCT06680232?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 45 participants. The study started on 2024-11-14. Estimated completion is 2026-12.
What conditions does trial NCT06680232 study?
This clinical trial studies the following conditions: Hepatitis B， Chronic.
What interventions are being tested in trial NCT06680232?
The interventions under investigation include: PBGENE-HBV (BIOLOGICAL).
Who is sponsoring clinical trial NCT06680232?
This trial is sponsored by Precision BioSciences, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06680232 being conducted?
This trial has 4 study locations across Massachusetts, Hong Kong. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatitis B， Chronic
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
The HOPE Study: Characterizing Patients With Hepatitis B and C
RECRUITING
-
Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B (B-Well 2)
ACTIVE NOT RECRUITING · Phase 3
-
Study of VIR-2218, VIR-3434, and/or PEG-IFNα in Subjects With Chronic Hepatitis B Virus Infection
ACTIVE NOT RECRUITING · Phase 2
-
Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B (B-Well 1)
ACTIVE NOT RECRUITING · Phase 3
-
Collection of Samples for the Clinical Evaluation of the Aptima HBV (Hepatitis B Virus) Quant (Quantification) Assay
COMPLETED
-
Entecavir Plus Adefovir Combination Therapy Versus Entecavir Monotherapy vs Therapy With Adefovir Plus Lamivudine for Chronic Hepatitis B Infected Subjects With Lamivudine-resistant Virus
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00804154 · 45 participants · Phase 1
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
- NCT01851694 · 45 participants · NA
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
- NCT02896335 · 45 participants · Phase 2
Palbociclib and Pembrolizumab In Central Nervous System Metastases
- NCT03454035 · 45 participants · Phase 1
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI